Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $191.77

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $191.77.

Several analysts have issued reports on ASND shares. Wells Fargo & Company raised their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. cut their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Wedbush reissued an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Oppenheimer reduced their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in shares of Ascendis Pharma A/S in the first quarter valued at approximately $288,000. ProShare Advisors LLC increased its position in shares of Ascendis Pharma A/S by 9.9% during the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock worth $608,000 after acquiring an additional 361 shares during the period. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 332 shares in the last quarter. Nan Fung Group Holdings Ltd purchased a new position in Ascendis Pharma A/S in the first quarter valued at $2,056,000. Finally, Capital International Investors boosted its holdings in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after purchasing an additional 10,044 shares during the period.

Ascendis Pharma A/S Trading Up 2.9 %

Shares of NASDAQ ASND opened at $134.60 on Wednesday. The stock has a market cap of $8.16 billion, a PE ratio of -16.66 and a beta of 0.66. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The company has a 50-day moving average of $133.04 and a 200 day moving average of $132.17.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.